

Clinical and Translational Science (CTS)
Conflict-of-Interest Statement

Policy on Conflicts of Interest and Financial Disclosures for Editors

Editors of the journal are required to disclose any potential conflicts of interest.

In instances in which a manuscript involves one or more companies for which an editor has a potential conflict of interest, that editor will excuse him/herself from the discussion and review of said manuscript.

In addition, an editor must disclose potential conflicts of interest of the types outlined below. These potential conflicts of interest do not need to be published on the journal website but must be disclosed to the editorial board. In instances in which a manuscript involves one or more companies for which an editor has one of the following types of potential conflict of interest, that editor will not participate in the discussion and review of said manuscript, although he or she may remain present while that discussion occurs.

- 1) Possession of equity of any kind in any single company, private or public, in the health care arena of \$10,000 or more by the author(s) or immediate family members, where immediate family members are defined as the spouses or domestic partners and children of the author(s).
- 2) Income derived from any single company, private or public, in the health care arena of \$10,000 or more per year by the author(s) or immediate family members, where immediate family members are defined as the spouses or domestic partners and children of the author(s), within 12 months of the initial submission of the paper to the journal. In this context, income is understood to include but not be limited to the following categories: honoraria, licensing fees, retainers, salary and payments in return for service as a speaker, advisory board member, consultant, or expert witness.
- 3) Research support provided by any single company, private or public, in the health care arena of \$10,000 or more per year to the author(s) or immediate family members, where immediate family members are defined as the spouses or domestic partners and children of the author(s), within twelve months preceding the initial submission of the paper to the journal. In this context, research support is understood to include but not be limited to the loan or donation of equipment.
- 4) Any association with any single company, private or public, in the health care arena that results in honoraria or compensation totaling between \$1,000 and \$9,999 by the editor(s) or immediate family members, where immediate family members are defined as the spouses or domestic partners and children of the editor(s), within twelve months preceding an editor's initial participation in a discussion of a manuscript for publication.

- 5) Any prospective association that may result in honoraria or compensation or any other financial relationship totaling \$1,000 or more.
- 6) Any close familial relation working for or having significant equity or other financial interest in any single company, private or public, in the health care arena.
- 7) Any prospective employment with any single company, private or public, in the health care arena.
- 8) Any close relationship with the individual(s) submitting a manuscript for publication in the journal, such individuals including students, former students, interns and mentors and collaborators on projects in the last three years.
- 9) Any possible competition between the research completed or manuscripts submitted by an editor for publication elsewhere and a manuscript submitted for publication in the journal.
- 10) Any personal benefit accruing to an editor through an acceptance or rejection of a specific paper being reviewed.

Executive Editorial Board Conflicts of Interest and Financial Disclosures

Editor	Interests/Commitments (over past 12 months)	Nature of Interests
Arthur M. Feldman, MD, PhD	Cardiokine, Inc.	Board member, Equity
	Arca Biopharma	Consultant
Scott A. Waldman, MD, PhD	Merck	Consultant
	Targeted Diagnostics & Therapeutics, Inc.	Research support, chair of SAB
Joseph M. Ahearn, MD	Cellatope Corporation	Research support, Equity
	Cypress Biosciences	Research support, Consultant
Jerrold J. Ellner, MD	N/A	
Ronald E. Gress, MD	N/A	
Terry Hyslop, PhD	National Cancer Institute	Honoraria
Walter J. Koch, PhD	N/A	
Michael Levine, MD	N/A	
Andre Terzic, MD, PhD	Cardio3Biosciences	Research support